Moderna announced state-of-the-art mRNA facility in Africa to manufacture up to 500 million doses per year
On Oct. 7, 2021, Moderna announced it will build a state-of-the-art mRNA facility in Africa with the goal…
-
-
CDC | COVID-19 | Infectious Disease | Vaccine
U.S. CDC reported more than 140,000 U.S. children lost a primary or secondary caregiver due to COVID-19 pandemic
On Oct. 7, 2021, the Centers for Disease Control and Prevention (CDC) reported that one U.S. child loses…
-
WHO, UN set out steps to meet world COVID vaccination targets
On Oct. 7, 2021, the World Health Organization (WHO) launched the Strategy to Achieve Global Covid-19 Vaccination by…
-
Vaxartﾠ began recruiting in global phase II COVID-19 oral tablet vaccine clinical trial
On Oct. 6, 2021, Vaxart announced that it had begun recruiting subjects for its Phase II COVID-19 oral…
-
AIM ImmunoTech published phase 1 clinical study data supporting the safety of Ampligen as intranasal therapy
On Oct. 6, 2021, AIM ImmunoTech released detailed safety data from a Phase 1 clinical study which supported…
-
Washington University School of Medicine in St. Louis led pediatric COVID-19 vaccine trial launched
On Oct. 6, 2021, Washington University School of Medicine announced the start of a pediatric COVID-19 vaccine clinical…
-
Lumen Bioscience awarded Federal funding to advance Covid-19 antibody cocktail through phase 2 clinical evaluation
On Oct. 6, 2021, Lumen Bioscience announced new development funding from the US Army for its Covid-19 monoclonal…
-
Johnson & Johnson submitted EUA amendment to FDA to support booster of single-shot COVID-19 vaccine
On Oct. 5, 2021, Johnson & Johnson announced it had submitted data to the U.S. Food and Drug…
-
Vaccination linked reduction of over a quarter million COVID-19 cases, 100,000 hospitalizations, and 39,000 deaths among seniors
On Oct. 5, 2021, a report from the U.S. Department of Health and Human Services (HHS) showed that…
-
Moderna announced EMA authorized third dose of COVID-19 vaccine for immunocompromised individuals aged 12 years and older
On Oct. 5, 2021, Moderna announced that the European Medicines Agency (EMA) had authorized a third dose of…
-
Biotechnology | CDC | COVID-19 | EPA | FDA | Infectious Disease | U.S. Congress | USDA | Vaccine
US Department of Defense announced mandatory coronavirus disease 2019 vaccination of civilian employees
On Oct. 4, 2021, the the Secretary of Defense directed the mandatory vaccination of Service members against the…
-
Dynavax and U.S. Department of Defense announce collaboration to develop adjuvanted plague vaccine
On Oct. 4, 2021, Dynavax Technologies and the U.S. Department of Defense (DOD) announced Dynavax has executed an…
-
Pfizer and BioNTech received CHMP positive opinion for COVID-19 vaccine booster in the European Union
On Oct. 4, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Merck and Ridgeback’s oral antiviral reduced risk of hospitalization or death for patients with COVID-19 in positive phase 3 study
On Oct. 1, 2021, Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine,…
-
Labcorp received EUA for at home collection kit for combined COVID-19 and flu detection
On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
-
Trevena announced results of TRV027 proof-of-concept study in COVID-19 patients
On Sept. 30, 2021, Trevena announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 vaccinated vs. non-vaccinated
This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…
-
Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination test
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
Biotechnology | COVID-19 | FDA | Infectious Disease | Influenza | Vaccine
Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
On Sept. 29, 2021, Pfizer and BioNTech positive top-line results from a Phase 3 study (B7471004) evaluating the…
-
NEJM published positive phase 3 trial resulted for REGEN-COV (casirivimab and imdevimab) to treat COVID-19
On Sept. 29, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) published positive detailed results…
-
VBI Vaccines announced preclinical data and Initiation of VBI-2905 clinical trial targeting broadened immunity against COVID-19
On Sept. 29, 2021, VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of…
-
Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19
On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveﾙ (casirivimab and…
-
NIAID issued new awards to fund ‘pan-coronavirus’ vaccines
On Sept. 28, 2021, the National Institute of Allergy and Infectious Diseases announced it had awarded approximately $36.3…
-
AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19
On Sept. 28, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…
-
University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Sept. 28, 2021, the University of Missouri researcher Kamlendra Singh led a team that analyzed protein sequences…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine | WHO
Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine
On Sept. 28, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
-
Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults
On Sept. 27, 2021, Pfizer announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for…
-
Pfizer announced Study of mRNA-based next generation flu vaccine program
On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…
-
Agriculture | Biotechnology | COVID-19 | Infectious Disease | USDA | Vaccine | Veterinary
USDA confirmed COVID-19 in Ferret in Florida
On Sept. 24, 2021, the U.S. Department of Agriculture’s (USDA) announced confirmation of SARS-CoV-2 in a ferret in…
-
Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccine
On Sept. 24, 2021, Moderna announced a supply agreement with the government of Peru for 20 million doses…
